What to know
In 2022 there were 2,377 clinical cases and 5,754 screening cases of Candida auris (C. auris) reported to CDC. Clinical cases are patients who are tested to determine a cause of infection and receive positive results for C. auris. States have voluntarily reported cases to CDC since 2013. The number of states and the number of cases are increasing each year. Clinical cases of C. auris became nationally notifiable in 2018.
Overview: Data and maps
Definitions
States use case definitions established by the National Notifiable Diseases Surveillance System (NNDSS) to count and report clinical and screening cases.
Clinical cases are patients who are tested to determine the cause or treatment of an infection and receive positive C. auris laboratory results. Clinical cases became nationally notifiable in 2018.
Screening cases are patients, typically without symptoms, who are screened for C. auris using swab test that receive results positive for C. auris. Screening is a measure to prevent the spread of C. auris in healthcare facilities.
Maps
The maps show the total number of clinical cases of C. auris reported by states during 2013-2016 and annual totals from 2017-2022. Time frames can be selected in the drop-down menu.
The total number of reported screening cases are listed below the map for each time period. Screening cases are not included on the maps.
Use the upper left corner drop-down menu to select a year or timeframe.
Reporting cases
C. auris infections are known to occur in healthcare facilities among people who are already sick. Healthcare facilities should notify their state or local health department about any new cases of C. auris. By reporting cases to health departments, healthcare facilities help improve surveillance and inform local prevention and control strategies.
State and local health departments submit case counts to CDC on a voluntary basis. Not all health departments report their cases to CDC.
Differences in detection and reporting
There are many different factors that influence the number of cases reported by states. States can appear to have fewer or greater numbers of cases based on the way they collect information.
These factors could include whether or not the disease is reportable (states set rules to report C. auris), access to diagnostic testing, or population size.
CDC assistance to public health partners
CDC works closely with public health and healthcare partners to prevent and respond to C. auris infections. CDC encourages all U.S. laboratories that identify C. auris to notify their state or local public health authorities.
State and local public health authorities should email Candidauris@cdc.gov:
- If they are not currently reporting cases and identify a new case.
- For assistance with tracking, and outbreak prevention and response.
CDC's AR Lab Network is available for assistance with C. auris identification and screening, to help improve detection and response to C. auris nationwide.
Message Mapping Guide
To view the NNDSS HL7 Healthcare-Associated Infections, Multidrug-Resistant Organisms (HAI MDRO) Message Mapping Guide, which includes C. auris and Carbapenemase Producing Carbapenem-Resistant Enterobacterales (CP-CRE), visit MMGs and Artifacts.